ORTEXORTEX News
Tracking LRN? Get live short interest, options flow, and signals on ORTEX.Sign up free →
LR
Earnings PreviewLRN

Stride Bears Dig In as Options Flash Extreme Caution

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 5 Aug 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

LRN heads into tonight's fiscal Q4 print carrying a 16% short position, a stock down sharply on the week, and the most defensive options positioning it has seen all year.

The options market is the most striking signal. The put/call ratio jumped to 0.83 on Tuesday — more than three standard deviations above its 20-day average of 0.54, the most extreme defensive tilt of the past 52 weeks. That spike sits against a backdrop of severe recent price weakness: the stock has fallen 16% over the past week to close at $80.45, even after a fractional recovery Tuesday. Education sector peers tell a contrasting story — LOPE, STRA, and MH all gained between 2% and 12% on the week — making LRN's drawdown look stock-specific rather than sector-wide.

Short interest adds weight to the bearish case. Bears hold 15.5% of the free float short, with that position growing roughly 6% over the past month as the stock fell. The short score has hovered around 69 for two weeks — high but not accelerating — and borrow availability remains comfortable at 212%, meaning there is no squeeze pressure in the lending market. Cost to borrow is just 0.58%. The bears are entrenched, but not being squeezed out.

The fundamental debate is sharpest on valuation. Bulls point to genuine growth — 7.5% revenue in Q2, improving enrollment, resolved platform issues — and a consensus target of $109, roughly 35% above the current price. The recent buyback program is cited as a confidence signal. Bears counter that, even after the week's selloff, the stock had already rallied 25% in premarket on Q2 results and may have pulled forward much of the good news. Morgan Stanley holds an Equal-Weight with a $95 target; Barrington Research and Canaccord Genuity both maintained Outperform and Buy ratings with $125 targets, though those notes are from April and January respectively. The broader analyst community has been lowering targets since late 2025, with cuts from multiple firms following prior earnings disappointments — the last print triggered a 2.7% one-day drop and a 4.1% five-day decline.

Institutional positioning adds a nuanced angle. Janus Henderson built a meaningful new stake of 863,000 shares through June, while Frontier Capital added nearly 1.4 million shares through May — fresh money moving in at higher prices than where the stock trades now. BlackRock, the largest holder at 15.3%, added modestly. On the insider side, the CFO received a 77,000-share award and immediately sold 38,000 shares at $97.71 on July 29 — a price well above today's level — generating $3.7 million in proceeds. That combination of institutional accumulation and insider monetisation captures the tension in the name precisely.

The print will test whether Stride's FY27 enrollment and margin guidance is strong enough to justify a re-rating back toward analyst targets — or whether the stock's 16-week run into earnings already extracted most of the premium.

Stocks in this article

See the live data behind this article on ORTEX.

Open LRN on ORTEX →

How this article was generated

Generated
5 Aug 2026, 04:23
Data as of
5 Aug 2026, 04:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.